Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Oligonucleotides: Global Markets" report has been added to ResearchAndMarkets.com's offering. The Global Oligonucleotides Market was valued at USD...
-
- Drumify has produced multiple Grammy-winning and multi-platinum records for many artists, including Drake, NBA YoungBoy, $UICIDEBOY$, Lecrae and Anuel AA - Marketplace expected to result in...
-
Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Shoals Technologies Group
-
NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Shoals Technologies...
-
MELVILLE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Two new models – the ColorStream 8200 and 8110 – will look to build on the success of the ColorStream 8000 series of high-speed, web-fed inkjet...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 25, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Shoals Technologies Group,...
-
Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Shoals Technologies Group, Inc. (NASDAQ: SHLS)
-
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
-
Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to...